TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02844816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study: NCT00371475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAXUS Liberté-SR
Description: Paclitaxel-Eluting Coronary 38 mm Stent

Intervention type: DEVICE
Group type: OTHER
Intervention: TAXUS™ Express
Description: Paclitaxel-Eluting Coronary Stent System
Study: NCT02703077

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon dilation of the papilla
Description: Using a hidrostatic balloon the major papilla will be dilated to facilitate the stone removal
Study: NCT00565552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silicone gel (Dermatix®)
Description: The half one the scar to treat was randomised among patients. After regular cleaning of the skin around the scar one half was thinly creamed with the silicone gel from medial to lateral and let dry for 5 minutes. It was done twice daily.
Study: NCT01408212

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Description: Acupuncture treatment will be performed by licensed doctors in Korean Medicine using 0.20 mm (diameter) X 0.30 mm (length) sized disposable acupuncture on seven to ten consecutive days after admission to the Korean Medicine Hospital of Pusan National University. At least two sessions and a maximum of five sessions of acupuncture therapy will be administered per day. Acupuncture points consist of common points and additional points selected for typical complaints common in patients under chemotherapy. These points are as follows.~* Common points: LI4 (bilateral), LU5 (bilateral), LU7 (bilateral), BL13 (bilateral), BL23 (bilateral), SP3 (bilateral), LU9 (bilateral), ST36 (bilateral) and CV22~* Additional points Nausea/vomiting PC6 (bilateral) Dyspepsia: CV12, LU6 (bilateral) Insomnia: Yintang, KI5 (bilateral) Pain: Ashi points (tender spots)
Study: NCT03205475

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alternate Coaching and Video Feedback Phase 1
Description: Alternates each week between live/tele-health coaching (coaching) or Video review and call (feedback)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alternate Coaching and Video Feedback Phase 1
Description: Alternates each week between live/tele-health coaching (coaching) or Video review and call (feedback)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alternate Coaching and Video Feedback Phase 1
Description: Alternates each week between live/tele-health coaching (coaching) or Video review and call (feedback)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly Coaching in Phase 1
Description: Weekly coaching (live or telehealth)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly Coaching in Phase 1
Description: Weekly coaching (live or telehealth)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly Coaching in Phase 1
Description: Weekly coaching (live or telehealth)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly Coaching plus Intensive Refresher Course Phase 2
Description: Continue weekly coaching with senior trainer and add one week intensive refresher course
Study: NCT02703077

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EHL (electrohydraulic lithotripsy)
Description: With a probe a direct view lithotripsy will be performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP (Endoscopic retrograde cholangiopancreatography)
Description: Endoscopic procedure to identify and treat biliary diseases

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP (Endoscopic retrograde cholangiopancreatography)
Description: Endoscopic procedure to identify and treat biliary diseases
Study: NCT01729455

Intervention type: BIOLOGICAL
Intervention: BENLYSTA
Description: As prescribed.~Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus.

Intervention type: OTHER
Intervention: SLE treatment
Description: As prescribed.~At baseline, SLE treatment must include an immunosuppressant. During the registry, SLE treatment may include any of the following (alone or in combination): immunosuppressants, corticosteroids, antimalarials, other biologics, investigational agents for SLE, as clinically indicated.

Intervention type: OTHER
Intervention: SLE treatment
Description: As prescribed.~At baseline, SLE treatment must include an immunosuppressant. During the registry, SLE treatment may include any of the following (alone or in combination): immunosuppressants, corticosteroids, antimalarials, other biologics, investigational agents for SLE, as clinically indicated.
Study: NCT03070886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given orally (PO)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given IM
Study: NCT03205475

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly Coaching plus Intensive Refresher Course Phase 2
Description: Continue weekly coaching with senior trainer and add one week intensive refresher course
Study: NCT03070886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study: NCT03459937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha Yoga Intervention
Description: Hatha Yoga will focus on a restorative style of Hatha yoga. Total duration will begin at 100 minutes per week and will gradually progress in 4-week intervals until achieving the prescribed dose of 300 min/wk (5 days per week for 60 minutes per day). While attending the behavioral group sessions the participants will also engage in a supervised yoga session with a trained yoga instructor. To facilitate the additional 4 days of unsupervised yoga, we will provide yoga videos that mimic the asanas (poses) and flow patterns that are taught in the supervised yoga sessions. The intervention includes prescribed dietary recommendations based on the participants' baseline body weight, and self-monitoring diaries, meal plans, and sample recipes will be provided. Intervention lessons will also include information related to behavior strategies for achieving the recommended calorie and fat intake goals. Participants will also be provided weekly group intervention sessions across the study period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vinyasa Yoga Intervention
Description: Vinyasa Yoga will focus on a more vigorous form of yoga. Total duration will begin at 100 minutes per week and will gradually progress in 4-week intervals until achieving the prescribed dose of 300 min/wk (5 days per week for 60 minutes per day). While attending the behavioral group sessions the participants will also engage in a supervised yoga session with a trained yoga instructor. To facilitate the additional 4 days of unsupervised yoga, we will provide yoga videos that mimic the asanas (poses) and flow patterns that are taught in the supervised yoga sessions. The intervention includes prescribed dietary recommendations based on the participants' baseline body weight, and self-monitoring diaries, meal plans, and sample recipes will be provided. Intervention lessons will also include information related to behavior strategies for achieving the recommended calorie and fat intake goals. Participants will also be provided weekly group intervention sessions across the study period.
Study: NCT02295397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food
Description: food provocation, skin testing, blood sampling
Study: NCT01187862

Intervention type: DRUG
Group type: OTHER
Intervention: caffeine, efavirenz, losartan, omeprazole, metoprolol, chlorzoxazone and midazolam
Study: NCT03824626

Intervention type: DIAGNOSTIC_TEST
Intervention: TEVAR patients
Description: Computed Tomography Angiography (CTA) will be performed using a 16-slice unit before and after intravenous administration of 100 mL of iodinated contrast material. Phase contrast-Magnetic Resonance (pc-MRI) will be performed using a 1.5-T unit with 40-mT/m gradient power and a four-channel cardio-thoracic coil. ECG-triggered, free-breathing through plane, and in-plane pc-MRI sequences will be performed for phase-velocity mapping of aortic and branches flow. Ad hoc processing of preoperative CTAs, based on 3D multiplanar reconstruction, will be performed with 3Mensio Vascular software 8.0® (3Mensio Medical Imaging B.V.), which provides specific functions for automatic measurements.
Study: NCT03199729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slip-only training
Description: Subjects in this arm will receive overground, slip specific perturbation training only. The total perturbation training trials received by this group will be 24 but the protocol will consist of a total of 70-75 trials (to match the training length and time of Combined slip and trip training group).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trip-only training
Description: Subjects in this arm consisting of a total of 24 trials of trip specific training delivered in an identical sequence (mixed with non-trip trials) as the Group with slip only training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined slip+trip training
Description: Subjects in this arm will receive training consisting of repeated exposure to both slips and trips with a total of 24 slips plus 24 trips to keep the number of trials of each perturbation same as the perturbation specific training groups (slip only and trip only), however, the total dose will be doubled. The total trials walked (perturbed + unperturbed) will be 75.
Study: NCT03205475

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly Coaching plus Peer Coaching Phase 2
Description: Continue weekly coaching with senior trainer and add weekly peer coaching from another interventionist in the region who is at high fidelity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly Coaching plus Peer Coaching Phase 2
Description: Continue weekly coaching with senior trainer and add weekly peer coaching from another interventionist in the region who is at high fidelity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Feedback Only Phase 2
Description: Receive video feedback and calls only
Study: NCT04278469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy Drugs, Cancer
Description: Clinical high and genomic low Hormone Receptor-positive early breast cancer patients with or without adjuvant chemotherapy
Study: NCT03961464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-cycloserine
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose
Study: NCT01082653

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous bone marrow-derived stem cells
Description: All patients will receive a unique one-time intrathecal infusion of the cell product suspended in infusion medium.
Study: NCT03205475

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Feedback Only Phase 2
Description: Receive video feedback and calls only
Study: NCT06120478

Intervention type: OTHER
Intervention: observe
Description: observational study

Intervention type: OTHER
Intervention: observe
Description: observational study
Study: NCT00516685

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human rEGF-P64K/Montanide Vaccine
Study: NCT00705341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone
Description: Inhaled corticosteroid approved for treatment of asthma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone
Description: Inhaled corticosteroid approved for treatment of asthma
Study: NCT04438616

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dome magnetic attachment
Description: * All patients will receive complete denture before implant installation .~* The CBCT examination should be take~* patients received infiltration local anesthesia~* A crestal incision is made using No. 15 c blade .~* Full sequential drilling under copious saline irrigation will be made . insertion of two implant by the contra angle handpiece with special adaptor~* We connect magnetic attachment(dome) on complete denture by pick up procedure at day of implant installation.~* Implant stability will be measured using smart peg /osstell at the day of implant installation and after 2,4,8,12 weeks.~* Patient satisfaction measure
Study: NCT02327000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Description: GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Description: GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 300mg
Description: GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 300mg
Description: GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 300mg
Description: GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day)
Study: NCT02785913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taselisib
Description: Given PO
Study: NCT03567109

Intervention type: OTHER
Intervention: hand laterality judgment task
Description: participants are asked to identify laterality of the hand presented on the screen
Study: NCT04438616

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: flat magnetic attachment
Description: * All patients will receive complete denture before implant installation .~* The CBCT examination should be take~* patients received infiltration local anesthesia.~* A crestal incision is made using No. 15 c blade~* Full sequential drilling under copious saline irrigation will be made as indicated by the company guide lines. insertion of two implant by the contra angle handpiece with special adaptor~* We connect magnetic attachment(flat) on complete denture by pick up procedure at day of implant installation.~* Implant stability will be measured using smart peg /osstell at the day of implant installation and after 2,4,8,12 weeks.~* Patient satisfaction measure in 2 weak and after 12 weak by Denture satisfaction questionnaire
Study: NCT00417521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Based Treatment
Study: NCT01625442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saffron tablet
Description: Saffron tablets 100 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Barberry tablet
Description: Barberry tablets 200 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets received daily for 45 days
Study: NCT03107208

Intervention type: DRUG
Group type: OTHER
Intervention: Glargine
Description: A dose of glargine (Lantus) will be given subcutaneously either early in the management of DKA (study group) or upon resolution of DKA (control group).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine
Description: A dose of glargine (Lantus) will be given subcutaneously either early in the management of DKA (study group) or upon resolution of DKA (control group).

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)
Description: All participants will be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA in order to better understand blood glucose control during DKA. This is an optional part of the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)
Description: All participants will be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA in order to better understand blood glucose control during DKA. This is an optional part of the study.
Study: NCT01472822

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omija extract.
Description: Omija extract 1.2g/day for 12weeks
Study: NCT01472822

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1.2g/day for 12weeks
Study: NCT02426008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Growth Factors and Cytokine adding to embryo culture media

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Intervention
Description: Nothing to Add
Study: NCT03567109

Intervention type: OTHER
Intervention: hand laterality judgment task
Description: participants are asked to identify laterality of the hand presented on the screen

Intervention type: OTHER
Intervention: hand laterality judgment task
Description: participants are asked to identify laterality of the hand presented on the screen
Study: NCT01280526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin and CHOP
Description: Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin and CHOP
Description: Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin and CHOP
Description: Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin and CHOP
Description: Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
Study: NCT02371902

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MODULITH® SLK, STORZ MEDICAL AG, Switzerland
Description: Three sessions were carried out, with the time interval between sessions spanning between 48 and 72 hours. In each session, 2400 pulses were administered with energy flux density (EDF) ranging from 0.14 and 0.20 mJ/mm2, depending on the maximum tolerated pain of each patient. Analgesics or local anaesthetics were not administered before, during or after treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoultrasound™, Medisport S.r.l., Italy
Description: Cryo-US therapy was performed in a continuous emission modality, using an ultrasound emission power rating of 1,8 Watt/cm2, and a temperature of -2˚C, for a total of 12 sessions lasting 20 minutes each. The treatment was performed in 3 weeks (4 daily sessions per week).
Study: NCT02030964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFMO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Study: NCT04031326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LENA Home
Description: LENA Home is a 13-week curriculum designed to add an early-language focus to existing home visiting or parent education programs for children ages birth to three. It employs LENA wearable audio recorder technology and targeted content to help parents and other caregivers increase interactive talk. There are 13 weekly one-on-one sessions, including modules on parent-child reading and increasing verbal interaction during typical home activities. Sessions include videos, practical techniques, and feedback from LENA recordings via intuitive reports to help parents talk more with their children. LENA Home reports provide data on adult words spoken to the child (AWC) and conversational turns (CTC). LENA Home has been shown to increase interactive talk and child language ability and informs parents how much they are talking with their children in an objective way.
Study: NCT02812082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web-based patient education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaire
Study: NCT01727817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabetes Assistant (DiAs)
Description: A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
Study: NCT03626701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device
Description: Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex® Ag Wound Dressing
Description: Application of Mepilex® Ag Wound Dressing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional autografting (only when indicated)
Description: When indicated, conventional autografting in accordance with Investigator's standard practice

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional autografting (only when indicated)
Description: When indicated, conventional autografting in accordance with Investigator's standard practice
Study: NCT00868647

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiofrequency ablation (RFA)
Description: Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
Study: NCT03541148

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oncoxin-Viusid
Description: Oncoxin-Viusid supplement before/during/after standard surgical and adjuvant treatment or chemotherapy.